Previous 10 | Next 10 |
EAGAN, Minn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) ...
2023-10-10 11:40:59 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With artificial intelligence ( AI ) showing no signs of cooling, we could see a $1.8 billion opportunity by 2030. AI is expected to help students learn better and faster, alread...
Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Pr...
2023-08-11 01:30:30 ET Predictive Oncology press release ( NASDAQ: POAI ): Q2 GAAP EPS of -$0.98. Revenue of $0.5M (+25.0% Y/Y). Concluded the second quarter of 2023 with $14.8 million in cash and cash equivalents, compared to $22.1 million as of December 31, 2022, and...
2023-08-10 23:56:08 ET Predictive Oncology, Inc. (POAI) Q2 2023 Earnings Conference Call August 10, 2023 17:30 ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob My...
PITTSBURGH, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncol...
Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Pr...
EAGAN, Minn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) ...
Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, its extensive biorepository of tumor samples, and its Clinical Laboratory Improvement Amendments (“CLIA”) lab...
Surrounded by world renowned universities and medical centers, Predictive Oncology is part of the next generation of Pittsburgh’s innovation ecosystem PITTSBURGH, July 18, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its ...
News, Short Squeeze, Breakout and More Instantly...
Predictive Oncology Inc. Company Name:
POAI Stock Symbol:
NASDAQ Market:
Predictive Oncology Inc. Website:
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (“GPCRs”). GPCRs are cell surface membrane receptors believed to play a...
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annu...
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. More closely mimicking human tissue architecture than traditional 2D a...